TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY
K Hamptona, P Knoeblb, J Odgaard-Jensenc, O Stasyshynd, JJT Zawc, JS Neergaardc, B Zulfikare, GG Fabbronf
a Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
b Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria
c Novo Nordisk A/S, Søborg, Denmark
d Academy of Medical Sciences of Ukraine, Lviv, Ukraine
e Department of Pediatric Hematology/Oncology, Istanbul University Oncology Institute, Istanbul, Türkiye
f Novo Nordisk Brasil, São Paulo, Brazil
Read
272
Timeswas read the article
151
Total PDF
121
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 20 | 24 | 44 |
| 2024 April | 28 | 18 | 46 |
| 2024 March | 20 | 24 | 44 |
| 2024 February | 15 | 15 | 30 |
| 2024 January | 6 | 9 | 15 |
| 2023 December | 12 | 21 | 33 |
| 2023 November | 11 | 26 | 37 |
| 2023 October | 9 | 14 | 23 |
